Can we consider fludarabine full dose i.v. busulfan a reduced intensity conditioning regimen?

被引：0
|
作者：
Chunduri, S [1 ]
Jessop, E [1 ]
Dobogai, L [1 ]
Peace, D [1 ]
Saunthararajah, Y [1 ]
Chen, YH [1 ]
Mahmud, N [1 ]
Maynard, V [1 ]
Hoffman, R [1 ]
Rondelli, D [1 ]
机构：
[1] Univ Illinois, Chicago, IL USA
来源：
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2005年 / 11卷 / 02期
关键词：
D O I：
10.1016/j.bbmt.2004.12.073
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
73
引用
收藏
页码：25 / 26
页数：2
相关论文
共 50 条
  • [1] Fludarabine/full dose i.v. busulfan conditioning regimen in allogeneic PBSC transplantation for high risk patients
    Chunduri, S.
    Dobogai, L. C.
    Peace, D.
    Saunthararajah, Y.
    Quigley, J.
    Chen, Y. -H.
    Boccuni, P.
    Hoffman, R.
    Mahmud, N.
    Beri, R.
    Hurter, E.
    Rondelli, D.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007, 13 (02) : 84 - 84
  • [2] Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both?
    S Chunduri
    L C Dobogai
    D Peace
    Y Saunthararajah
    J Quigley
    Y-H Chen
    N Mahmud
    E Hurter
    R Beri
    D Rondelli
    Bone Marrow Transplantation, 2008, 41 : 935 - 940
  • [3] Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both?
    Chunduri, S.
    Dobogai, L. C.
    Peace, D.
    Saunthararajah, Y.
    Quigley, J.
    Chen, Y-H
    Mahmud, N.
    Hurter, E.
    Beri, R.
    Rondelli, D.
    BONE MARROW TRANSPLANTATION, 2008, 41 (11) : 935 - 940
  • [4] Busulfan/Fludarabine/Thymoglobulin as a Reduced Intensity Conditioning Regimen for Lymphoid Malignancies.
    Sekhar, Jeevan
    Stockerl-Goldstein, Keith
    Zhang, Qin
    Cashen, Amanda F.
    Abboud, Camille N.
    Uy, Geoffrey L.
    Westervelt, Peter
    DiPersio, John F.
    Vij, Ravi
    BLOOD, 2009, 114 (22) : 1294 - 1294
  • [5] Comparable toxicity between Fludarabine/full dose i.v. Busulfan and fludarabine/melphalan in allogeneic PBSC transplantation.
    Chunduri, S
    Jessop, E
    Dobogai, LC
    Peace, D
    Saunthararajah, Y
    Chen, YH
    Mahmud, N
    Maynard, V
    Hoffman, R
    Rondelli, D
    BLOOD, 2004, 104 (11) : 340B - 341B
  • [6] Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS
    Andersson, Borje S.
    de Lima, Marcos
    Thall, Peter F.
    Wang, Xuemei
    Couriel, Daniel
    Korbling, Martin
    Roberson, Soonja
    Giralt, Sergio
    Pierre, Betty
    Russell, James A.
    Shpall, Elizabeth J.
    Jones, Roy B.
    Champlin, Richard E.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (06) : 672 - 684
  • [7] High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen
    Geddes, Michelle
    Kangarloo, S. Bill
    Naveed, Farrukh
    Quinlan, Diana
    Chaudhry, M. Ahsan
    Stewart, Douglas
    Savoie, M. Lynn
    Bahlis, Nizar J.
    Brown, Christopher
    Storek, Jan
    Andersson, Borje S.
    Russell, James A.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (02) : 220 - 228
  • [8] Hematopoietic cell transplantation with reduced intensity conditioning regimen using fludarabine/busulfan and fludarabine/melphalan for primary immunodeficiency diseases
    Nishimura, Akira
    Aoki, Yuki
    Ishiwata, Yasuyoshi
    Inoue, Maiko
    Ichimura, Takuya
    Ueyama, Junichi
    Matsumoto, Kazuaki
    Inoue, Kento
    Hiroki, Haruka
    Ono, Shintaro
    Okano, Tsubasa
    Tanaka, Mari
    Miyamoto, Satoshi
    Ashiarai, Miho
    Miyawaki, Reiji
    Yamagishi, Chika
    Tezuka, Mari
    Okawa, Teppei
    Hoshino, Akihiro
    Endo, Akifumi
    Yasuhara, Masato
    Kamiya, Takahiro
    Mitsuiki, Noriko
    Ono, Toshiaki
    Yanagimachi, Masakatsu
    Isoda, Takeshi
    Tomizawa, Daisuke
    Nagasawa, Masayuki
    Kajiwara, Michiko
    Takagi, Masatoshi
    Mizutani, Shuki
    Kanegane, Hirokazu
    Imai, Kohsuke
    Morio, Tomohiro
    BONE MARROW TRANSPLANTATION, 2019, 54 : 390 - 391
  • [9] Clofarabine ± Fludarabine with Once Daily i.v. Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and MDS
    Andersson, Borje S.
    Valdez, Benigno C.
    de Lima, Marcos
    Wang, Xuemei
    Thall, Peter F.
    Worth, Laura L.
    Popat, Uday
    Madden, Timothy
    Hosing, Chitra
    Alousi, Amin
    Rondon, Gabriela
    Kebriaei, Partow
    Shpall, Elizabeth J.
    Jones, Roy B.
    Champlin, Richard E.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (06) : 893 - 900
  • [10] Age-dependent pharmacokinetic profile of single daily dose i.v. busulfan in children undergoing reduced-intensity conditioning stem cell transplant
    W T Tse
    R Duerst
    J Schneiderman
    S Chaudhury
    D Jacobsohn
    M Kletzel
    Bone Marrow Transplantation, 2009, 44 : 145 - 156
12345